CHANG NANCY T 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Oct 16, 2017
Insider Transaction Report
Form 4
CHANG NANCY T
Director
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$0.28/sh−30,000$8,400→ 0 totalExercise: $10.90Exp: 2027-06-08→ Common Stock (30,000 underlying) - Disposition to Issuer
Common Stock
2017-10-13$11.18/sh−70,000$782,600→ 0 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.03/sh−30,000$60,900→ 0 totalExercise: $9.15Exp: 2025-06-11→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
- [F2]The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- [F3]Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").